Interesting to follow MAIA who as LWS said seems to have caught a tail wind from the recent Geron FDA ADCOM results. The MAIA leadership has bought shares but has an interesting background:
“ Dr. Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.”
Litigation economics… maybe there will be some IP issues at some point. Throwing down the gauntlet? He is a specialist on the subject of economic damages, but damages to whom? Geron is turning into a powerhouse, might not be the best time or circumstance to pick a fight.
Down the road, way down the road
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: Down the road, way down the road
News about Dr. Stan Smith (Will patent considerations bring Geron and MAIA together in some form of collaboration?)
============
============
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
March 22, 2024 3:00 PM EDT Tweet Share E-mail
Dr. Smith has participated in every MAIA funding round
CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
On March 11, 2024, MAIA entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,043,587 shares of the Company’s common stock, and warrants to purchase up to 2,043,587 shares of the Company’s common stock, at a price per share of $1.17. The combined gross proceeds from the private placement, closed on March 14, 2024, were approximately $2.9 million, prior to deducting offering expenses payable by the Company.
-
jayfish101
- Posts: 128
- Joined: Tue Feb 23, 2016 5:48 pm
Re: Down the road, way down the road
I have to wonder about a company that calls a PH.D., Mr. Smith. Not too aware there folks.
Re: Down the road, way down the road
jay --- Most men that I know with PhDs, that do not have medical degrees, prefer to be called (Mr.).
The interesting thing about Mr. Smith, is that his background is litigation economics. Assuming that the FDA does not create some last-minute difficulty with the NDA approval and takes ODAC's positive recommendations, there will be considerable interest in patent overlap. It was once said, that if there existed a patent about Telomeres and Telomerase, it likely belonged to Geron. This next chapter will be very interesting.
It seems to me, since the 2 companies are working on different parts of the cancer spectrum, they should be able to work out an arrangement that is beneficial to both.
The interesting thing about Mr. Smith, is that his background is litigation economics. Assuming that the FDA does not create some last-minute difficulty with the NDA approval and takes ODAC's positive recommendations, there will be considerable interest in patent overlap. It was once said, that if there existed a patent about Telomeres and Telomerase, it likely belonged to Geron. This next chapter will be very interesting.
It seems to me, since the 2 companies are working on different parts of the cancer spectrum, they should be able to work out an arrangement that is beneficial to both.
-
jayfish101
- Posts: 128
- Joined: Tue Feb 23, 2016 5:48 pm
Re: Down the road, way down the road
The designation of Dr. was originally first assigned only to 'PHD's. Much later.MD, DVD, etc. jumped on the bandwagon. I find all PHD's I know, and I know several hundred of them, do not like to be called Mr. It's either Dr. or their first name.
Re: Down the road, way down the road
I will refer to him as Dr. Smith.
To me, the subject of interest is the "litigation economics" and the fact that Sergei (Dr. Sergei Gryaznov, now at MAIA)) spent so much time with both companies developing Imetelstat and THIO as important cancer medicines. Which patents, with his name belong to Geron, and which patents (if any) are being used in the development of other cancer drugs for MAIA?
I believe both medicines are telomerase inhibitors. Dr. Smith (on MAIAs board) has likely looked at this, as both medicines (hopefully) find their way to markets. Imetelstat is way in the lead, but THIO will likely gain traction when the FDA soon approves Imetelstat (after ODAC's recommendations).
To me, the subject of interest is the "litigation economics" and the fact that Sergei (Dr. Sergei Gryaznov, now at MAIA)) spent so much time with both companies developing Imetelstat and THIO as important cancer medicines. Which patents, with his name belong to Geron, and which patents (if any) are being used in the development of other cancer drugs for MAIA?
I believe both medicines are telomerase inhibitors. Dr. Smith (on MAIAs board) has likely looked at this, as both medicines (hopefully) find their way to markets. Imetelstat is way in the lead, but THIO will likely gain traction when the FDA soon approves Imetelstat (after ODAC's recommendations).